Amneal Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMRX research report →
Companywww.amneal.com
Amneal Pharmaceuticals, Inc. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE.
- CEO
- Chirag K. Patel
- IPO
- 2018
- Employees
- 8,300
- HQ
- Bridgewater, NJ, US
Price Chart
Valuation
- Market Cap
- $3.90B
- P/E
- 32.88
- P/S
- 1.28
- P/B
- -88.59
- EV/EBITDA
- 10.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 38.66%
- Op Margin
- 11.80%
- Net Margin
- 4.02%
- ROE
- -144.72%
- ROIC
- 12.64%
Growth & Income
- Revenue
- $3.02B · 8.05%
- Net Income
- $72.06M · 161.65%
- EPS
- $0.23 · 160.53%
- Op Income
- $423.09M
- FCF YoY
- 22.63%
Performance & Tape
- 52W High
- $15.42
- 52W Low
- $7.02
- 50D MA
- $12.60
- 200D MA
- $11.86
- Beta
- 1.32
- Avg Volume
- 1.85M
Get TickerSpark's AI analysis on AMRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Autor Deborah M. | sell | 34,819 |
| May 7, 26 | BUCHI J KEVIN | other | 34,819 |
| May 6, 26 | BUCHI J KEVIN | other | 19,824 |
| May 7, 26 | BUCHI J KEVIN | other | 34,819 |
| May 7, 26 | Autor Deborah M. | other | 34,819 |
| May 6, 26 | Autor Deborah M. | other | 19,824 |
| May 7, 26 | Autor Deborah M. | other | 34,819 |
| May 7, 26 | George Jeffrey P. | other | 34,819 |
| May 6, 26 | George Jeffrey P. | other | 19,824 |
| May 7, 26 | George Jeffrey P. | other | 34,819 |
Our AMRX Coverage
We haven't published any research on AMRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMRX Report →